SNCA and Parkinson disease: In addition, using selected, specific fragments as a therapeutic target to generate antibodies against them (the detection of these fragments which can promote the aggregation of α-synuclein to form oligomers and exert their toxicity to the body) are all pivotal biomarkers for PD diagnosis or prognosis.